{{'Search' | translate}}
 

PipettesP10 pipette

Company: Gilson
Catalog#: FA10002M
Bio-protocol()
Company-protocol()
Other protocol()

Polyamine Transport Assay Using Reconstituted Yeast Membranes
Author:
Date:
2021-01-20
[Abstract]  

ATP13A2/PARK9 is a late endo-/lysosomal P5B transport ATPase that is associated with several neurodegenerative disorders. We recently characterized ATP13A2 as a lysosomal polyamine exporter, which sheds light on the molecular identity of the unknown mammalian polyamine transport system. Here, we describe step by step a protocol to measure radiolabeled polyamine transport in reconstituted vesicles from yeast cells overexpressing human ATP13A2. This protocol was developed as part of our recent publication (van Veen et al., 2020) and will be useful for characterizing the transport function of other putative polyamine transporters, such as isoforms of the P5B transport ATPases.

[摘要]  [摘要] ATP13A2 / PARK9是一种晚期内/溶酶体P5B转运ATPase,与多种神经退行性疾病有关。我们最近将ATP13A2表征为溶酶体多胺出口者,这为未知的哺乳动物多胺转运系统的分子身份提供了线索。在这里,我们逐步描述了从过量表达人ATP13A2的酵母细胞中测量重组囊泡中放射性标记的多胺转运的方案。该方案是我们最新出版物的一部分(van Veen等,2020),将有助于表征其他假定的多胺转运蛋白的转运功能,例如P5B转运ATPase的同工型。


[背景] ATP13A2 / PARK9编码一种普遍表达的晚期内-/溶酶体膜蛋白,与一系列神经退行性疾病有关,例如早发性帕金森氏病(Di Fonzo等,2007 ;Lin等,2008)和Kufor -Rakeb综合征(伴痴呆的早期帕金森病)(Ramirez等,2006 ;Park等,2011)。ATP13A2属于P型转运ATPase ,是一类活性转运蛋白,由于ATP水解而暂时形成磷酸中间产物(Kuhlbrandt ,2004年)。ATP13A2是P5亚家族的成员,该家族已在20多年前通过基因组测序鉴定出来(Axelsen和Palmgren ...

Multiple Stepwise Gene Knockout Using CRISPR/Cas9 in Escherichia coli
Author:
Date:
2018-01-20
[Abstract]  With the recent implementation of the CRISPR/Cas9 technology as a standard tool for genome editing, laboratories all over the world are undergoing one of the biggest advancements in molecular biology since PCR. The key advantage of this method is its simplicity and universal applicability for species of any phylum. Of particular interest is the extensively studied Gram-negative bacterium Escherichia coli, as it is considered as the workhorse for both research and industrial purposes. Here, we present a simple, robust and effective protocol using the CRISPR/Cas9 system in combination with the λ Red machinery for gene knockout in E. coli. Crucial in our procedure is the use of a double-stranded donor DNA and a curing strategy for removal of the guide RNA encoding plasmid ... [摘要]  随着CRISPR / Cas9技术作为基因组编辑的标准工具的最近实施,全世界的实验室正在经历PCR以来分子生物学方面最大的进步之一。这种方法的关键优点是其简单和普遍适用于任何物种的门。特别感兴趣的是广泛研究的革兰氏阴性细菌大肠杆菌,因为它被认为是研究和工业用途的主力。在这里,我们提出了一个简单,强大和有效的协议,使用CRISPR / Cas9系统结合λ红色基因敲除机器。大肠杆菌。在我们的程序中最重要的是使用双链供体DNA和固化策略来去除导向RNA编码质粒,其允许在仅仅两个工作日后开始新的突变。我们的方案允许多个具有高诱变效率的基因敲除株,适用于高通量的方法。

【背景】革兰氏阴性细菌大肠杆菌是生物技术工程中最重要的生物之一。已在能源,农业,食品生产,生物技术,医药等不同行业的各种流程中成功实施。由于不断的技术进步,生物技术部门正在迅速发展。特别是,CRISPR / Cas9技术可能是PCR(分子)生物学最大的革命(Ledford,2015)。简而言之,CRISPR / Cas9保护细菌免受诸如质粒和病毒等侵入性遗传因子的影响(Marraffini,2015)。利用这种从原核生物获得的免疫系统,已经开发了基于CRISPR / Cas9系统的基因组编辑的非常有力的工具(Jinek等人,2012)。

CRISPR / ...

Comments